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Abstract
Cellular FLICE-like inhibitory protein (c-FLIP) has been identified as a protease-dead, 
procaspase-8-like regulator of death ligand-induced apoptosis, based on observations that c-FLIP 
impedes tumor necrosis factor-α (TNF-α), Fas-L, and TNF-related apoptosis-inducing ligand 
(TRAIL)-induced apoptosis by binding to FADD and/or caspase-8 or -10 in a ligand-dependent 
fashion, which in turn prevents death-inducing signaling complex (DISC) formation and 
subsequent activation of the caspase cascade. c-FLIP is a family of al ternatively spliced variants, 
and primarily exists as long (c-FLIPL) and short (c-FLIPS) splice variants in human cells. 
Although c-FLIP has apoptogenic activity in some cell contexts, which is currently attributed to 
heterodimerization with caspase-8 at the DISC, accumulat ing evidence indicates an anti-apoptotic 
role for c-FLIP in various types of human cancers. For example, small interfering RNAs (siRNAs) 
that specifically knocked down expression of c-FLIPL in diverse human cancer cell lines, e.g., 
lung and cervical cancer cells, augmented TRAIL-induced DISC recruitment, and thereby 
enhanced effector caspase stimulation and apoptosis. Therefore, the outlook for the therapeutic 
index of c-FLIP-targeted drugs appears excellent, not only from the efficacy observed in 
experimental models of cancer therapy, but also because the current understanding of dual c-FLIP 
action in normal tissues supports the notion that c-FLIP-targeted cancer therapy will be well 
tolerated. Interestingly, Taxol, TRAIL, as well as several classes of small molecules induce c-
FLIP downregulation in neoplastic cells. Efforts are underway to develop small-molecule drugs 
that induce c-FLIP downregulation and other c-FLIP-targeted cancer therapies. In this review, we 
assess the outlook for improving cancer therapy through c-FLIP-targeted therapeutics.
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INTRODUCTION
Chemotherapeutic drug resistance is a major clinical problem and an important cause of 
treatment failure in cancer. One of the important goals of molecular oncology is to identify 
the underlying drug resistance mechanisms, with the prospect that more effective and novel 
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therapies for cancer can be developed. Several mechanisms have been found to cause 
resistance to chemotherapeutic agents in cancer cells in vitro [1-5]. Identifying novel 
mechanisms of resistance to chemotherapeutic agents will assist in the design of more 
effective strategies to overcome resistance in cancer cells. Defects in apoptotic signaling in 
malignant cells contribute to the drug resistance in various cancer types [6]. Furthermore, 
death receptor-mediated apoptosis is deficient in some drug resistant cancer cells. Therefore, 
strategies to lower the thresholds for triggering apoptosis in various cancers may lead to new 
and more effective therapeutic regimens. The death-inducing cytokine tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) holds enormous promise as a cancer therapeutic 
due to its highly selective apoptosis-inducing action on neoplastic versus normal cells 
[7-10]. However, to exploit this opportunity, the problems of TRAIL resistance in cancer 
must first be overcome [11-15]. Cellular FLICE-like inhibitory protein (c-FLIP), a 
catalytically inactive caspase-8/-10 homologue, is involved in TRAIL and chemotherapeutic 
drug resistance in a wide range of human malignancies [11, 13, 16-20]. Substantial levels of 
c-FLIP are expressed in deadly human cancers such as ovarian, colon, glioblastoma, breast, 
colorectal, and prostate cancers, and it is implicated in the TRAIL resistance owing to its 
overexpression in a substantial proportion of these malignancies [21-24]. Furthermore, 
interference with c-FLIP expression sensitizes these tumor cells to TRAIL and other tumor 
necrosis factor-related death ligands, such as FAS ligand, in experimental models [17, 20, 
25, 26]. c-FLIP is an important modulator of the initiator procaspases-8 and -10 and thereby 
regulates life and death in normal cells and tissues, and renders resistance to death receptor-
mediated apoptosis in various cancer cells. In addition to its function as an apoptosis 
modulator, c-FLIP exerts other cellular functions including increased cell proliferation and 
tumorigenesis [27]. Moreover, dysregulation of c-FLIP expression has been associated with 
diseases such as cancer and autoimmune diseases [28, 29]. Therefore, c-FLIP is a critical 
target for therapeutic intervention. In this review, we assess the outlook for improving the 
outcome of cancer therapy by targeting c-FLIP and exploring the possibility of its 
degradation and/or decreasing its expression in order to provide a potentially safe approach 
to the treatment of cancer. The possibility of developing novel modalities of cancer therapy 
that improve the efficacy and lessen the toxicity of cancer chemotherapy by targeting 
specific c-FLIP isoforms is discussed.
APOPTOSIS SIGNALING PATHWAYS
Two well-studied pathways are involved in apoptosis, the mitochondrion-initiated pathway 
(Fig. 1) and the cell surface death receptors pathway (Fig. 2) [30-32]. In the mitochondrial 
pathway, cytochrome c, certain caspases, apoptosis-inducing factor, Smac/DIABLO, an 
inhibitor of apoptosis protein (IAP)-binding protein, and other apoptosis-inducing factors are 
released from the mitochondrial intramembrane space to the cytosol [33]. Once released, 
cytochrome c and dATP bind to apoptotic proteinase-activating factor-1 (Apaf-1), and this 
complex along with adenine nucleotides promotes procaspase-9 autoactivation [34], which 
in turn activates caspases-2, -3, -6, -7, -8, and -10. In the death receptor-mediated apoptosis 
pathway (e.g. Fas/Fas ligand interaction and cell death), the initiator caspases-8 and -10 
activate the downstream caspases including caspase-3. Active caspases-8 and -10 are known 
to cleave a pro-apoptotic Bcl-2 family member, Bid, and the truncated Bid induces 
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mitochondrial cytochrome c release [32-35], thereby linking the two pathways. After 
activation, both caspases-8 and -9 activate caspase-3, which in turn cleaves other caspases 
and many cellular proteins including fodrin, protein kinase C, poly(ADP-ribose) 
polymerase, gelsolin, and DNA fragmentation factor-45 (DFF45) [32, 36, 37]. A third 
pathway also has been recently identified [38]. In this pathway, Bid is cleaved downstream 
of the point of Bcl-2 action, catalyzed by caspase-3, which occurs upstream of caspase-8 
activation, thereby acting as a potential feedback loop for amplifying the apoptosis-
associated release of cytochrome c from the mitochondria [38].
c-FLIP AND THE DEATH RECEPTOR APOPTOSIS PATHWAY
The TNF receptor (TNFR) superfamily consists of cell surface receptors that are activated 
by cognate ligands and signal proliferation, differentiation, and apoptosis (Fig. 2). Death 
receptors in the TNFR superfamily include the TNF-α receptor, Fas (APO-1/CD95), and 
TRAIL receptors DR4 (also known as TRAIL receptor 1) and DR5 (also known as TRAIL 
receptor 2). Other TNFR superfamily members protect against apoptosis by serving as cell 
surface decoy receptors that compete for death ligand binding but cannot induce apoptosis 
[39, 40]. The death receptors contain an intracellular death domain (DD) which is essential 
for inducing apoptosis upon receptor ligation; the decoy receptors cannot signal apoptosis 
for lack of a functional DD [40]. The DD is a canonical 80 amino acid cytoplasmic docking 
surface in death receptors, that upon ligand binding to the receptor, homotypically binds a 
similar domain in the death adaptor protein FADD or TRADD [41]. Death adaptor proteins 
also have a death effector domain (DED) that forms a distinct docking surface for 
homotypic binding of initiator (apical) caspases. Once the initiator caspases are recruited to 
death receptor-tethered FADD, the DISC (death-inducing signaling complex) is formed, 
whereupon the caspases are trans-proteolyzed, dimerized, and rendered active; executioner 
caspase activation and apoptosis ensues. An important regulator of death receptor-induced 
death is c-FLIP, which binds to procaspases-8, -10 and FADD, and when overexpressed, can 
protect tumor cells from apoptosis. This supports the notion that cancer therapeutics that 
target apical proteins in the death receptor pathway, e.g., caspase-8 and -10 isoforms and c-
FLIP variants (see below), may have a favorable therapeutic index. In the following sections 
we will discuss apoptosis induced by TRAIL and other chemotherapeutic agents such as 
Taxol (paclitaxel) and doxorubicin, through downregulation of c-FLIP variants, and address 
the possibilities for using c-FLIP as a therapeutic target.
STRUCTURE OF c-FLIP
Initially, viral FLICE-inhibitory proteins (v-FLIPs) were identified by a bioinformatic search 
for novel virus-encoded apoptotic regulatory molecules containing a DED [42-44]. 
Following the characterization of v-FLIPs, the mammalian cellular homologue was 
identified and called c-FLIP [45]. Animal models have revealed that c-FLIP plays an 
important role in T cell proliferation and heart development. Moreover, abnormal c-FLIP 
expression has been found in various diseases such as cancers, multiple sclerosis, 
Alzheimer’s disease, diabetes mellitus, and rheumatoid arthritis. So far, 11 distinct c-FLIP 
splice variants have been reported, three of which are expressed as proteins: the 26 kDa 
short form (c-FLIPS), the 24 kDa form of c-FLIP (c-FLIPR) and the 55 kDa c-FLIPL [46, 
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47] (Fig. 3). The structures of c-FLIPS and the v-FLIPs are similar, except that the two 
DEDs of c-FLIPS are followed by 20 amino acids that appear to be crucial for its 
ubiquitylation and targeting for proteasomal degradation [48]. c-FLIPR also contains two 
DEDs but lacks the additional carboxy (C)-terminal amino acids that are present in c-FLIPS. 
The C-terminus of c-FLIPL is longer than that of c-FLIPS and closely resembles the 
structure of caspases-8 and -10 [47], but this region of c-FLIPL does not contain a functional 
caspase domain. This lack of caspase activity is the result of the substitution of several 
amino acids, particularly the crucial cysteine residue in the catalytic domain which is 
necessary for the catalytic activity of caspases [49]. Additionally, c-FLIPL harbors a 
caspase-8 cleavage site at position Asp-376 (LEVD); c-FLIPL cleavage at this site produces 
the proteolytic fragment variant p43c-FLIP [50, 51].
c-FLIP FUNCTION
As discussed above, c-FLIP has been identified as a protease-dead, procaspase-8-like 
regulator of death ligand-induced apoptosis [27, 45, 52, 53]. It has been shown that c-FLIP 
interferes with TNF-α, Fas-L, and TRAIL-induced signaling pathways by binding to FADD 
and/or caspase-8/10 in a ligand-dependent fashion, which in turn prevents DISC formation 
and subsequent activation of the caspase cascade [27, 53, 54]. However, studies using c-
FLIP-deficient mice support a dual function for c-FLIP by confirming a role for c-FLIP in 
Fas L- and TNF-α-induced apoptosis, and revealing that c-FLIP has a similar function to 
caspase-8 in heart development [55]. Nonetheless, a now extensive literature encompassing 
diverse types of human cancer cells indicates that the action of c-FLIP is generally anti-
apoptotic in cancer cells.
While the precise mechanism of c-FLIP variant regulation of apoptosis remains elusive, the 
profound structural differences between human c-FLIP variants clearly indicate distinct 
regulatory roles for c-FLIPL and c-FLIPS in apoptosis. In fact, c-FLIPS inhibits TRAIL-
induced DISC formation and apoptosis [56], while c-FLIPL is responsible for the above 
described dual functions whereby it inhibits Fas-induced caspase-8 activation when 
expressed at high levels, but enhances caspase-8 activation when its expression level is low 
[53-59]. These opposing c-FLIPL functions may reflect observations that c-FLIPL activates 
caspases-8 and -10 in vitro by forming heterodimeric enzyme molecules with a substrate 
specificity and catalytic activity indistinguishable from caspase-8 homodimers, despite the 
fact that c-FLIPL is protease dead [60]. In addition, accumulating evidence has revealed that 
c-FLIP may be an effector that contributes to survival signaling by the Akt, ERK, and NF-
κB signaling pathways [41, 57, 61, 62] (Fig. 4).
It has been demonstrated that overexpression of c-FLIPL activates NF-κB and ERK 
signaling by binding to adaptor proteins in each pathway, such as TNFR-associated factors 1 
(TRAF1) and 2 (TRAF2), receptor-interacting protein 1 (RIP), and Raf-1 [63, 64] (Fig. 4). 
The caspase-8 processed N-terminal fragment of c-FLIPL (p43cFLIP) is more efficient than 
c-FLIPL at recruiting TRAF2 and RIP1, leading to more robust NF-κB activation [51, 
62-65]. Golks et al. [66] recently showed that in nonapoptotic cells, c-FLIP and the 
procaspase-8 heterodimer result in a novel NH2-terminal fragment of c-FLIP (p22-FLIP) 
which is the key mediator of NF-κB activation by directly binding to the IKK complex. 
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These results provide a new mechanism of c-FLIP-mediated NF-κB activation. Recently, 
Chang et al. [67] demonstrated that TNF-α-mediated JNK activation increases turnover of 
the NF-κB-induced c-FLIP. This is not the result of direct c-FLIP phosphorylation, but 
rather depends on JNK-mediated phosphorylation and activation of the E3 ubiquitin ligase 
Itch which specifically ubiquitinates c-FLIP and induces its proteasomal degradation. Thus, 
JNK antagonizes NF-κB during TNF-α signaling by promoting the proteasomal elimination 
of c-FLIPL.
In addition to inhibiting caspase-8 and -10 activation [68], c-FLIPL interacts with Daxx (a 
death domain-associated protein that has been implicated in proapoptosis and transcriptional 
regulation) and prevents Fas-induced JNK activation [69]. Thus, c-FLIPL acting on both the 
FADD- and Daxx-mediated signaling pathways may be involved in completely inhibiting 
Fas-induced cell death. Furthermore, Nakajima et al. [70] demonstrated that c-FLIPL 
directly interacts with a JNK activator, MAP kinase kinase 7 (MKK7), in a TNF-α-
dependent manner and inhibits the interactions of MKK7 with MAP/ERK kinase kinase 1, 
apoptosis-signal-regulating kinase 1, and TGF-β-activated kinase 1. This interaction of c-
FLIPL with MKK7 might selectively suppress JNK activation (Fig. 4).
Recent results also indicate that the calcium/calmodulin-dependent protein kinase II (CaMK 
II)-mediates the upregulation of c-FLIP, thereby protecting melanoma cells from TRAIL-
induced apoptosis. Treating resistant cells with the CaMK II inhibitor KN-93 inhibited 
CaMK II activity, reduced c-FLIP expression, inhibited c-FLIP phosphorylation, and 
rescued Fas agonistic antibody (CH-11) sensitivity [19, 71]. Targeting this pathway may 
provide novel therapeutic strategies in treating cancers with upregulated CaMK II. 
Interestingly, phosphorylation of c-FLIP variants by CaMK II appears to promote c-FLIPL 
recruitment to the DISC and inhibit TRAIL-induced apoptosis [19, 71], but phosphorylation 
of c-FLIPL by protein kinase C or the bile acid glycochenodeoxycholate results in decreased 
c-FLIPL recruitment to the DISC and increased sensitivity of hepatocellular carcinoma cells 
to TRAIL-triggered apoptosis [72]. Thus, the particular site of phosphorylation in c-FLIPL 
appears to influence the functional outcome of this protein on apoptosis.
c-FLIPS also suppress apoptosis by inhibiting caspase-8 activation, although at different 
levels of procaspase-8 processing [73, 74]. c-FLIPL induces a conformation of procaspase-8 
that triggers partial but not complete proteolytic processing, while in contrast c-FLIPS even 
prevents partial procaspase-8 activation at the DISC [74]. Using an in vitro induced 
proximity assay, Boatright et al. [60] provide evidence that c-FLIPL is an activator of 
caspase-8/-10 and demonstrate that the resulting heterodimer is enzymatically active with a 
substrate specificity identical to that of the caspase-8 homodimer.
Increased expression of c-FLIP can alter cell cycle progression and enhance cell 
proliferation and carcinogenesis. Overexpression of c-FLIPL inhibited the ubiquitinylation 
and proteasomal degradation of -β-catenin, resulting in an increase of the target gene cyclin 
D1, colony formation, and invasive activity in prostate cancer cells. The FLIP/β-catenin/
cyclin D1 signals contributing to colony formation and invasion were reversed by selective 
silencing of c-FLIP expression [41]. Similarly, c-FLIPL, in cooperation with FADD, 
enhances canonical Wnt signaling by inhibiting proteasomal degradation of β-catenin, thus 
Safa et al. Page 5
Curr Cancer Drug Targets. Author manuscript; available in PMC 2015 August 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
suggesting a new mechanism involved with tumorigenesis, in addition to inhibiting Fas 
signaling [75] (Fig. 4). Recently, Wang et al. [76] demonstrated that c-FLIP overexpression 
is also significantly related to the presence of HR-HPV infection during the progression of 
cervical squamous cell cancer and that c-FLIP is an early marker of cervical carcinogenesis. 
Moreover, c-FLIP overexpression accelerated progression to androgen independence by 
inhibiting apoptosis in LNCaP prostate tumors implanted in nude mice [77]. Similarly, c-
FLIP is also an independent prognostic indicator in colorectal carcinomas [56], and its 
expression in Burkitt’s lymphomas is also associated with a poor clinical outcome and could 
be a reliable prognostic factor in this type of cancer [78]. Furthermore, recent studies show 
that c-FLIP expression may contribute to the carcinogenesis and aggressiveness of 
endometrial carcinomas and may serve as a useful prognostic factor for this tumor [79, 80]. 
Overexpression of c-FLIPL also increases the hypoxia-inducible factor-1α (HIF1α) [81]. 
Overexpression of HIF1α can result in genes responsible for global changes in cell 
proliferation, metastasis, and invasion.
TRANSCRIPTION AND TRANSLATION REGULATION OF c-FLIP
Several transcription factors are known to downregulate c-FLIPL and c-FLIPS expression. 
E2F1, a transcription factor that plays a crucial role during S phase progression and 
apoptosis, triggers apoptosis in various lung adenocarcinoma cell lines by specific 
downregulation of c-FLIPS leading to caspase-8 activation at the DISC. c-FLIPS 
downregulation by E2F1 occurs at the transcriptional level though its mechanism remains to 
be found. The specific overexpression of c-FLIPS is also seen in human lung 
adenocarcinomas with low levels of E2F1 [82].
Androgen receptor (AR) is a ligand-activated transcription factor that mediates androgen 
action and is essential for the growth, function, and cell differentiation of the prostate gland. 
Recently, Gao et al. [77] demonstrated that the prostate apoptosis response factor-4 (Par-4) 
functions as an androgen receptor coactivator. This factor directly interacts with the DNA-
binding domain of the androgen receptor, increases interaction of this receptor with DNA, 
and elevates androgen receptor-dependent transcription. Interestingly, Par-4 is recruited onto 
the c-FLIP promoter in the presence of androgens. The binding to Par-4 to the promoter 
enhanced c-FLIP expression and this elevated expression was reversed by the expression of 
a dominant-negative Par-4. Enhanced c-FLIP expression was associated with prostate cancer 
progression to the androgen-resistant stage [77].
Another regulator of c-FLIP expression is p53 tumor suppressor protein. p53 may exert 
transcriptional upregulating effects on the c-FLIP gene and also has potent effects on 
promoting the degradation of c-FLIP protein [83-86]. Moreover, the gene encoding c-FLIP 
is a direct target of c-myc-mediated transcriptional repression. Chromatin 
immunoprecipitation and luciferase reporter analyses have shown that c-myc binds and 
represses the c-FLIP promoter. Overexpression of c-myc or activation of myc-estrogen 
receptor (ER) decreased c-FLIP levels in both cell culture and mouse models of c-myc-
induced tumorigenesis, while knocking down c-myc using siRNA increased c-FLIP 
expression [87].
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Li et al. [88] reported that c-FLIPL is transcriptionally regulated by the activator protein-1 
(AP-1) family member protein c-Fos and that MG-132, an inhibitor of the proteasome, 
sensitizes TRAIL-resistant prostate cancer cells by inducing c-Fos and repressing c-FLIPL. 
Moreover, c-Fos, which is activated by MG-132, negatively regulates c-FLIPL by direct 
binding to the putative promoter region of the c-FLIPL gene. In addition to activating c-Fos, 
MG-132 activates c-Jun, another AP-1 family member. c-Fos heterodimerizes with c-Jun to 
form AP-1 and repress transcription of c-FLIPL.
Recent results demonstrated that c-FLIP is also regulated at the translational level. Panner et 
al. [89, 90] showed that TRAIL resistance in glioblastoma multiforme cells (GBM) is the 
result of overexpression of c-FLIPS, and that c-FLIPS expression is in turn translationally 
increased by activation of the Akt-mammalian target of rapamycin (mTOR)-p70 S6 kinase 1 
(S6K1) pathway. Conversely, inhibition of mTOR or its target S6K1 suppressed 
polyribosomal accumulation of c-FLIPS mRNA, c-FLIPS protein expression, and promoted 
TRAIL sensitivity in GBM cells. An mTOR-independent pathway can also act through a Ral 
effector protein, RalBP1, to suppress cdc42-mediated activation of S6 kinase and the 
translation of the protein c-FLIPS [90, 91]. However, not much is known about Ral except 
that it is an effector of Ras oncogenesis. The Ral proteins (RalA and RalB) are small 
GTPases and their activity is controlled by the RalGEF family of proteins: RalGDS, Rgl, 
and Rlf [92]. Activated Ral molecules interact with Ral effectors, including RalBP1 (a cdc42 
GTPase-activating protein) [93]. Recently, Panner et al. have shown that (1) the RalA 
pathway is linked to both the translational control and the tumor-suppressive pathways, (2) 
RalA activation is linked to TRAIL sensitivity via the suppression of c-FLIPS levels, and (3) 
RalA activation is linked to c-FLIPS and the extrinsic cell death pathway via RalBP1 and 
cdc42 [90]. These interesting results define an mTOR-independent link between RalA and 
translation. These authors also demonstrated that RalBP1 serves in a membrane-bound, 
GTPase-activating protein (GAP)-dependent manner to link RalA activation to cdc42 
suppression, thereby leading to a decrease in c-FLIPS expression and enhancing TRAIL-
induced apoptosis.
c-FLIP DEGRADATION
c-FLIP is predominantly degraded by the ubiquitin-proteasome degradation system [94]. 
Both c-FLIP isoforms can be degraded by the proteasome, but c-FLIPS appears to be 
particularly sensitive to ubiquitylation and proteasomal degradation, partly due to two 
crucial lysine residues in the C-terminal 20 amino acids that are unique to c-FLIPS [48]. The 
sensitivity of c-FLIPS to ubiquitin-mediated degradation adds a novel concept to DISC 
regulation and its control of apoptosis [48]. Downregulation of c-FLIPL and c-FLIPS due to 
degradation is observed in cells treated with various apoptosis-inducing agents. The cyclin-
dependent kinase inhibitor flavopiridol degrades c-FLIP and increases apoptosis, which in 
turn can be reversed by an inhibitor of the ubiquitin-proteasome system [95]. Combined 
treatment with the anticancer agent 3,3′-diindolylmethane and TRAIL led to significant 
degradation of c-FLIP, predominantly via the ubiquitin-proteasome degradation system [94]. 
Moreover, Peroxisome Proliferator-Activated Receptor γ (PPARγ) agonists sensitize cancer 
cells to TRAIL by ubiquitination and proteasome-dependent c-FLIP degradation [96, 97].
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Proteasome inhibitors are a new class of drugs that decrease proliferation and induce 
apoptosis in a variety of hematologic and solid malignancies [98]. Interestingly, several 
proteasome inhibitors lead to the downregulation of c-FLIPL and c-FLIPS [99, 100].
c-FLIP VARIANTS AS TARGETS FOR CANCER THERAPY
Strategies to lower the threshold for triggering cancer cell apoptosis may lead to new and 
more effective therapeutic regimens for cancer. TRAIL holds enormous promise as a cancer 
therapeutic due to its highly selective apoptosis-inducing action on neoplastic versus normal 
cells [2]. However, to exploit this opportunity, the problem of TRAIL resistance in cancer 
must first be overcome. While c-FLIPL may function as a fine-tuned regulator that manifests 
dual pro- and anti-apoptotic actions during development and in normal adult tissues, 
accumulating evidence indicates an anti-apoptotic role for c-FLIP in diverse types of human 
cancer [11, 13, 16, 18, 20, 101-104]. Notably, recent reports demonstrated that small 
interfering RNAs (siRNAs) that specifically knocked down the expression of c-FLIPL or c-
FLIPS in cancer cell lines of various types augmented TRAIL- and chemotherapy-induced 
apoptosis [11, 17, 25, 105]. Therefore, the outlook for the therapeutic index of c-FLIP-
targeted drugs appears excellent, not only because of the therapeutic efficacy observed in 
models of c-FLIP targeting in cancer therapy with TRAIL, but also because the current 
understanding of c-FLIP action in normal tissues supports the notion that c-FLIP-targeted 
cancer therapy will be well tolerated.
There does not appear to be a “handle” to inhibit c-FLIP function with small molecule 
ligands, since the cytoprotective DISC binding is mediated by highly conserved DEDs 
which function by homotypic binding. However, small molecules that induce c-FLIP 
downregulation and sensitize neoplastic cells to apoptosis induction by TRAIL have been 
identified in global, unbiased chemical screens. Our results revealed that forced expression 
of c-FLIPL or c-FLIPS caused resistance to apoptosis in the CCRF-HSB-2 leukemia cell line 
[68] and the MCF-7 breast cancer cell line (Wu CH, Day TW, Najafi F, and Safa AR, 
unpublished results). Moreover, c-FLIPL, but not c-FLIPS, inhibited apoptosis induced by 
the fluoropyrimidine 5-fluorouracil (5-FU), the topoisomerase-1 inhibitor irinotecan 
(CPT-11), and the DNA damaging agent oxaliplatin (OXA) in HCT116 colorectal cancer 
cells, suggesting that c-FLIPL is the more important splice form in mediating 
chemoresistance [20]. Furthermore, c-FLIP inhibits TRAIL-independent, DR5- and caspase 
8-dependent apoptosis in response to chemotherapy in colorectal cancer cells. We (Wu CH, 
Day TW, and Safa AR, unpublished results) and others [106] have found that MCF-7 cells 
overexpressing c-FLIP are resistant to Taxol. The c-FLIPL variant protects against apoptosis 
induced by a diverse group of chemotherapeutic drugs with different mechanisms of action 
[102, 103, 107]. c-FLIP also inhibits spontaneous death ligand-independent cell death [25, 
102], further supporting the notion that targeting c-FLIP may have therapeutic potential for 
cancer treatment. Cisplatin, camptothecin, and etoposide were all shown to downregulate c-
FLIPS expression in human malignant glioma cells [103, 108]. Moreover, doxorubicin 
decreased levels of c-FLIP, particularly c-FLIPS in prostate cancer cell lines, and sensitized 
these cells to TRAIL [109]. Overexpression of the c-FLIPL variant has been found in 
ovarian cancer cells resistance to cisplatin [110]. Interestingly, the damaged DNA-binding 
protein 2 (DDB2), a component involved in the genomic repair of UV damage, was recently 
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shown to be involved in the cross-resistance of a cisplatin-selected HeLa cell line (HR3) to 
Fas-inducing antibody and tumor necrosis factor (TNF)-α-mediated apoptosis [110]. The 
HR3 cell line exhibits enhanced expression of DDB2 and cross-resistance to UV-induced 
activation of caspases and apoptosis. The overexpression of DDB2 was shown to increase 
both endogenous and exogenous c-FLIP mRNA levels, and inhibition of c-FLIP by 
antisense oligonucleotides suppressed DDB2 protection, revealing that DDB2 regulates TNF 
signaling-mediated apoptosis via c-FLIP. Therefore, therapeutics capable of modulating the 
death-inducing ligands and/or chemotherapeutic agents by downregulating c-FLIP variants 
should hold enormous promise in future clinical trials.
We recently published the novel findings that Taxol downregulates c-FLIP (both c-FLIPS 
and c-FLIPL) in cancer cells [68], and that doses of the drug that induced concentration-
dependent apoptosis were sufficient to abrogate the expression of both c-FLIP variants (Fig. 
5). The significance of these findings to paclitaxel-induced neoplastic cell apoptosis was 
demonstrated by our results showing that transfection with an antisense c-FLIP plasmid 
abrogated c-FLIPS and c-FLIPL expression and sensitized cancer cells to Taxol [68]. These 
results demonstrate that c-FLIP isoforms are major contributing factors to cancer cell 
resistance to paclitaxel-induced apoptosis.
AGENTS KNOWN TO DOWNREGULATE c-FLIP
Many therapeutics capable of downregulating c-FLIP levels enhance the expression of the 
TRAIL receptor DR5, and in some cases enhance levels of both the DR4 and DR5 TRAIL 
receptors. One such agent is lexatumumab, a humanized agonistic monoclonal antibody 
specific for the DR5 receptor, which is currently in Phase I/II clinical trials in patients with 
advanced malignancies. Recently, lexatumumab was shown to decrease the expression of c-
FLIPL and increase the level of DR5 in primary and metastatic renal cell carcinoma [111]. 
Similarly, the induction of apoptosis by the proteasome inhibitors MG-132 and PS-341 
(bortezomib, VelcadeR) in primary chronic lymphocytic leukemia (CLL) cells and the 
Burkitt lymphoma cell line BJAB was associated with upregulation of TRAIL and its death 
receptors, DR4 and DR5, and decreased c-FLIP protein expression [99]. As mentioned 
earlier, c-FLIP is degraded via a ubiquitin-proteosome system. Therefore, PS-341 should 
increase c-FLIP and prevent apoptosis. Interestingly, Zhao et al. have shown that PS-341 
decreases c-FLIP at the gene level [112]. In contrast, Liu et al. reported that PS-341 
upregulates DR5 as well as c-FLIP and survivin in human non-small cell lung carcinomas 
(NSCLC) cells [113]. Thus, the effect of PS-341 on the regulation of c-FLIP expression may 
be cancer cell-type specific. A proposed central mechanism of action of PS-341 is the 
inhibition of NF-κB activation through inhibition of IκB degradation [114]. NF-κB 
activation results in upregulation of c-FLIP [115]. Thus, downregulation of the c-FLIP gene 
by PS-341 may be due to inhibition of NF-κB activation by this agent. PPARγ ligands exert 
PPARγ-independent effects on inducing DR5 expression and downregulating c-FLIP levels, 
leading to enhanced TRAIL-induced apoptosis [97]. Synthetic triterpenoids sensitize 
TRAIL-resistant T47D and MDA-MB-468 breast cancer cells to TRAIL-mediated apoptosis 
by downregulating c-FLIPL, and upregulate cell surface TRAIL receptors DR4 and DR5 in 
breast cancer cell [116]. Similarly, the p53 protein increased the sensitivity of testicular 
germ cells to mono-(2-ethylhexyl)phthalate-induced apoptosis by elevating the membrane 
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levels of DR5 and Fas and decreasing the intracellular level of c-FLIP [86]. Progesterone 
induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL 
overexpression [117].
Another class of agents known to downregulate c-FLIP expression are the histone 
deacetylases inhibitors (HDACi). These compounds are considered to be among the most 
promising agents for the developing novel cancer therapeutics [118, 119]. In diverse types of 
cancer cells, HDACi induce growth arrest, differentiation, and apoptosis. The results of 
clinical trials with several of these agents indicate that they are well tolerated at doses that 
have antitumor activity [119, 120]. Importantly, normal cells are almost always more 
resistant to HDACi than tumor cells [119, 120]. The mechanism of their antitumor activity is 
likely related at least in part to hyperacetylation of the promoter regions of the TRAIL and 
DR5 genes [121-123]. Co-treatment with the histone deacetylase inhibitor LAQ824 
enhanced the mRNA and protein expression of the death receptors DR5 and/or DR4, but 
reduced the c-FLIP mRNA and protein levels and increased TRAIL-triggered apoptosis 
[124].
Elucidating the mechanisms regulating c-FLIP expression in neoplastic disease may lead to 
c-FLIP-downregulating targeted therapeutics that are efficacious and well tolerated in 
combination with TRAIL, conventional chemotherapeutic agents, or other therapies that 
activate the caspase-8/10-dependent apoptosis pathway. This approach may be especially 
effective in human malignancies that overexpress c-FLIP, i.e., glioblastoma multiforme, 
prostate, colorectal, endometrial, ovarian, mesothelial, and lung cancer [11, 17, 20, 41, 79, 
89, 101, 125].
In an exciting twist in identifying regulators of TRAIL-triggered apoptosis, Jin et al. [126] 
used the intracellular death domain (DD) of DR5 as a target to screen a phage-displayed 
combinatorial peptide library. The DD of DR5 identified a peptide from the library that 
showed sequence similarity to a stretch of amino acids in the C-terminus of c-FLIPL. In 
vitro binding assays revealed that this peptide selectively interacted with the DD of DR5. 
Similarly, these authors demonstrated that full-length c-FLIPL and the C-terminal p12 
domain of c-FLIP interacted with DR5 both in vitro and in mammalian cells, and that this 
interaction was independent of TRAIL. Moreover, when cancer cells were treated with 
TRAIL, c-FLIPL was released from DR5 and FADD was recruited to the active DR5 
signaling complex. Of particular significance, a cellular membrane-permeable version of 
this peptide induces apoptosis in mammalian cells. Therefore, these results provide a basis 
for rationally designing peptidomimetic or small molecule targeted therapeutics which, by 
interacting with the C-terminal domain of c-FLIPL, release DR5 and subsequently form the 
active DR5 signaling complex for triggering apoptosis by TRAIL and/or chemotherapeutic 
agents in cancer cells resistant to these agents.
Selective c-FLIPL and c-FLIPS knockdown strategies to sensitize cancer cells to TRAIL 
may lead to combination therapies consisting of TRAIL plus innovative c-FLIP variant-
selective gene therapy strategies. c-FLIPL and c-FLIPS knockdown could provide significant 
clinical advances in the use of TRAIL in treating lung cancer. Similarly, many agents 
mentioned above abrogate expression of the c-FLIP variants, suggesting that these 
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experimental therapeutics have potential value to reverse cancer cell resistance to TRAIL, 
paclitaxel and cisplatin.
Oncolytic viruses are known to infect, replicate in, and eventually eliminate tumor cells 
without harming normal cells [127]. Reoviruses are oncolytic viruses that multiply 
preferentially in tumor cells that harbor activated ras family or ras-signaling pathways, while 
sparing normal cells [127]. Recently, Clarke et al. [128] demonstrated that reovirus infection 
results in the downregulation of c-FLIP and increased TRAIL-induced apoptosis in ovarian 
cancer cells, and overexpression of c-FLIP blocked reovirus-induced sensitization of these 
cells to TRAIL-induced apoptosis. Using oncolytic viruses aimed at downregulating c-FLIP 
may be potentially useful in combination with TRAIL and/or chemotherapeutic agents to 
eradicate cancer cells.
c-FLIPS and/or c-FLIPL serve as rational target(s) in various cancers for novel small 
molecule targeted therapeutics and/or gene therapy strategies., e.g., small molecule 
therapeutics that selectively downregulate c-FLIPS or c-FLIPL and gene therapy strategies 
that knock down a specific c-FLIP variant. Developing these innovative therapeutic 
strategies in conjunction with TRAIL and Taxol will potentially overcome the barrier of 
dose-limiting toxicity in cancer chemotherapy. Furthermore, rather than empirically 
combining cytotoxic drugs to attempt to enhance their therapeutic response, modulating 
specific targets in cancer cells based on rational preclinical design is the most logical 
approach to eradicate cancer. The validity of this approach in treating metastatic solid 
tumors is exemplified by the efficacy of targeted inhibition of the protein kinase c-Kit by 
imatinib mesylate (GleevecR) in the first-line treatment of metastatic gastrointestinal stromal 
tumor (GIST) [129]. TRAIL or chemotherapy resistance in diverse cancer cell types can be 
reversed by parallel treatment with other substances, such as agents known to downregulate 
c-FLIP variants.
CONCLUSION
Apoptosis is a mechanism of programmed cell death involving cellular signaling pathways 
that induce cells to self-destruct in response to specific cellular cues or environmental 
hazards. The mechanism of action of chemotherapeutic agents often involves the induction 
of cancer cell apoptosis, and resistance to apoptosis in these cells is a major contributing 
factor in drug resistance. Therefore, using targeted therapeutics to restore apoptosis 
signaling in cancer cells has great potential to improve the outcome of cancer chemotherapy. 
Several studies have demonstrated elevated c-FLIP levels in various tumor types suggesting 
that c-FLIP may be a relevant clinical target. The current state of the art reviewed in this 
article suggests that c-FLIP may represent an important clinical marker of drug resistance, 
and that targeting c-FLIP in combination with TRAIL or standard chemotherapies has 
therapeutic potential for treating cancer. The foregoing discussion justifies optimism that 
future cancer therapy will be improved by innovations that replace current standard 
chemotherapy with targeted therapy or combined chemotherapy with drug resistance-
reversing targeted therapy, e.g., combination regimens of chemotherapy and small molecule 
drugs that downregulate c-FLIP.
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Fig. (1). Mitochondrial death pathway
The mitochondrial pathway of apoptosis is usually caused by disruption of mitochondrial 
membrane potential (ΔΨm), release of cytochrome c, activation of caspase-9, and 
subsequent activation of downstream caspases-2, -3, -6, -7, -8 and -10, which eventually 
leads to apopto sis. On the other hand, caspase-dependent apoptosis induced by death 
receptor ligation (e.g., Fas ligand/Fas or TNF-α/TNF- α receptor) can function 
independently of the mitochondria by caspase-8 activation, which directly activates 
caspase-3, -6 and -7, or by causing proteolytic cleavage of the pro-apoptotic protein Bid to a 
truncated form (tBid), which in turn is inserted in the mitochondrial membrane and induces 
release of cytochrome c. Release of the apoptosis inducing factor (AIF) from mitochondria 
causes caspase-independent apoptosis.
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Fig. (2). The cell death receptor pathway
FAS-ligand, TNF-α, and TRAIL bind to their respective receptors leading to the recruitment 
of FADD via a death domain (DD) interaction. After FADD binding, the death effector 
domain (DED) of FADD interacts with the DEDs of procaspases-8 and -10 forming the 
death-inducing signaling compex (DISC). Following DISC formation, caspases-8 and -10 
are activated, disassociate from the DISC, and activate downstream effector caspases. c-
FLIP binds to procaspases-8, -10, and FADD, and inhibits DISC formation.
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Fig. (3). Structures of c-FLIP variants
Three c-FLIP variants, c-FLIPL, c-FLIPS, and c-FLIPR, contain two death effector domains 
(DEDs) at their N-termini. In addition to two DEDs, c-FLIPL contains a large (p20) and a 
small (p12) caspase-like domain without catalytic activity. c-FLIPS and c-FLIPR consist of 
two DEDs and a small C-terminus (adapted from [46]).
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Fig. (4). Model depicting the multifunctional roles of c-FLIP on various signaling pathways
As discussed in the text, in addition to its functional role in inhibiting apoptosis by binding 
to procaspases-8 and -10 and inhibiting their activation, c-FLIP also has the following 
functions: (1) initiating cell proliferation by recruiting and activating (a) downstream 
signaling proteins including TRAF, RIP, IKK, and NFkB, or (b) RAF and extracellular 
signal-regulated kinase (ERK), (2) controlling cell survival by activating Akt, JNK, and Wnt 
signaling pathways, and (3) participating in carcinogenesis.
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Fig. (5). Caspase-independent downregulation of c-FLIPL and c-FLIPS levels by Taxol
(a) CCRF-HSB-2 cells were treated with 0.5, 1, 5, 10, or 50 nM Taxol for 24 h. Cell lysates 
were subjected to immunoblot analysis using an anti-c-FLIP antibody. (b) MCF-7 cells were 
treated with 10, 100, or 500 nM Taxol for 48 h. Cell lysates were subjected to immunoblot 
analysis using an anti-c-FLIP antibody. (c) CCRF-HSB-2 cells were treated with 100 μM of 
z-VAD-fmk for 3 h followed by 10 nM Taxol for an additional 24 h. Immunoblot analysis 
was conducted on cell lysates treated with or without z-VAD-fmk using anti-c-FLIP 
antibodies. Equivalent loading was confirmed by reprobing the same blot with anti-β-actin.
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